KROS News & Events

Reports Q1 revenue $367,000, consensus $1.69M. "Continuing to progress our pipeline remains our top priority, setting the stage for future catalysts and growth opportunities," said Jasbir S. Seehra, President and Chief Executive Officer. "In addition, we are excited that our partner, Takeda Pharmaceuticals U.S.A., Inc., plans to advance elritercept into a Phase 3 clinical trial to evaluate elritercept as a treatment of anemia in myelofibrosis, broadening the indication opportunity beyond myelodysplastic syndromes."

Keros Therapeutics announced that it has entered into an agreement with the Massachusetts General Hospital, MGH, for the design of a Phase 2 clinical trial evaluating rinvatercept in patients with amyotrophic lateral sclerosis, ALS, within the Healey ALS MyMatch program, led by the Sean M. Healey & AMG Center for ALS at Mass General Brigham. "We are proud to be selected to the ALS MyMatch program to collaborate with the Healey & AMG Center at Mass General," said Jasbir Seehra, Ph.D., President and Chief Executive Officer of Keros. "Rinvatercept represents a potentially novel approach to treat patients with ALS. Based on the data we have generated to date, we believe there is a strong scientific rationale for the potential of rinvatercept to preserve muscle strength and function and improve quality of life in patients with ALS."

Keros Therapeutics announced that it presented additional data from its Phase 1 clinical trial of rinvatercept in healthy volunteers at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference. Clinical presentation: "Proteome Analysis in a Phase 1 Trial of KER-065, a Modified Activin Receptor Ligand Trap, Confirmed Target Engagement and Guides Clinical Development in Neuromuscular Diseases." Administration of rinvatercept led to changes in body composition consistent with activin and myostatin inhibition. An increase in muscle mass, decrease in fat mass and an increase in bone mineral density were observed. Proteomic data further demonstrated the mechanism of action of rinvatercept, including its observed effects on mitigating fibrosis and inflammation by inhibiting activins, consistent with the anti-fibrotic and anti-inflammatory effects observed preclinically. Changes in serum markers of energy metabolism indicated a shift in macronutrient requirements for muscle growth, which aligned with the observed increases in muscle mass. These data provide multiple lines of evidence that rinvatercept may potentially achieve sufficient activin inhibition across tissues of interest, at drug exposures that we anticipate targeting in DMD and ALS.